BioCryst Pharmaceuticals (BCRX) vs Replimune Group (REPL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Replimune Group (REPL) has outperformed BioCryst Pharmaceuticals (BCRX) over the past year, gaining 107.3% versus a gain of 3.6%. Over five years, REPL leads with a -34.2% price change compared with -42.1% for BCRX. BioCryst Pharmaceuticals is the larger company by market cap ($1.86 billion vs $1.81 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | REPL |
|---|---|---|
| Share price | $7.22 | $19.07 |
| Market cap | $1.86B | $1.81B |
| 1-day change | -1.37% | -0.83% |
| YTD return | -7.44% | +96.19% |
| 1-year return | +3.59% | +107.28% |
| 5-year return | -42.15% | -34.24% |
| Forward P/E | 8.44 | — |
| EPS (TTM) | $-1.28 | $-2.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $874.84M | — |
| Revenue growth (YoY) | +94.10% | — |
| Net income (latest FY) | $263.86M | $-313.94M |
| Gross margin | 97.82% | — |
| Operating margin | 38.98% | — |
| Net margin | 30.16% | — |
| 52-week high | $11.22 | $23.54 |
| 52-week low | $6.23 | $1.50 |
| Distance from 52-week high | -35.65% | -18.99% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +183.24% | +33.72% |
| Average volume | 4.97M | 2.48M |
| Shares outstanding | 257.30M | 94.80M |
| Employees | 435 | 465 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- REPL has outperformed BCRX by 103.7 percentage points over the past year.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Replimune Group
REPL stock →Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 465 employees
BCRX vs REPL FAQ
Which is bigger, BioCryst Pharmaceuticals or Replimune Group?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $1.86B compared with $1.81B for Replimune Group (REPL).
Which stock has performed better over the past year, BCRX or REPL?
REPL returned +107.28% over the past 12 months, compared with +3.59% for BCRX (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Replimune Group in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.